Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

GLP-1 receptor agonist combined progesterone and endometrial cancer risk in patients with nonmalignant uterine disease

GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases

JAMA Network Open

Citation & Authors

JAMA Netw Open. 2026;9(2):e2558205.

Ting-Tai Yen; Tina Yi Jin Hsieh; Gin-Yi Lee; Eugene P Toy; James Cheng-Chung Wei; Edward J Tanner

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

importance

The incidence of endometrial cancer (EC) continues to rise, particularly among individuals with obesity and metabolic abnormalities, creating a need for effective strategies targeting both hormonal and metabolic risks.

purpose

To evaluate EC risk in patients with endometrial hyperplasia (EH) or benign uterine conditions receiving progestogen alone or with a GLP-1 receptor agonist (GLP-1RA).

Design, site and participants

This TriNetX cohort study evaluated EC and hysterectomy in adult women with EH or benign uterine conditions who received progestogen between May 1, 2005, the GLP-1RA approval date, and December 31, 2022. Deidentified electronic health records were identified using ICD-10 codes; data were obtained on February 23, 2025. Four treatment strategies were compared: GLP-1RA plus progestogen versus progestogen alone; GLP-1RA plus progestogen versus metformin plus progestogen; triple therapy with GLP-1RA, metformin, and progestogen versus metformin plus progestogen; and triple therapy versus progestogen alone. Subgroup analyses of GLP-1RA plus progestogen versus progestogen alone were stratified by progestogen administration route, risk level, BMI, and age.

exposed

GLP-1RA, progestogen, and/or metformin.

Main outcomes and measures

The primary outcome was incident EC; the secondary outcome was subsequent hysterectomy.

result

There were 18,414 patients receiving GLP-1RA plus progestogen and 426,406 receiving progestogen alone; their mean ages were 43.1 years (SD 10.2) and 35.2 years (10.9), respectively. The combination group had a significantly lower risk of EC than the progestogen-only group (HR 0.34; 95% CI 0.27–0.44), consistently across subgroups defined by route of administration, baseline risk, BMI, and age. GLP-1RA plus progestogen was also associated with a lower risk of EC than metformin plus progestogen (0.30; 0.15–0.59). Triple therapy was associated with a lower risk of EC than either metformin plus progestogen (0.37; 0.25–0.53) or progestogen alone (0.44; 0.29–0.66). The GLP-1RA plus progestogen group had lower rates of hysterectomy at 2 years (0.47; 0.42–0.53) and 5 years (0.59; 0.54–0.64).

Conclusion and significance

Among women with benign uterine conditions or endometrial hyperplasia, GLP-1RA plus progestogen was associated with a lower risk of EC. Its applicability and underlying mechanisms require further investigation.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.

Key findings

Compared with progestogen alone, concomitant GLP-1 receptor agonist use was associated with a lower risk of endometrial cancer (HR 0.34; 95% CI 0.27–0.44).

This was an observational study. Its clinical applicability and potential mechanisms require further investigation.